Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial

Capdevila, J; Tafuto, S; Krogh, M; Teulé, A; Garcia-Carbonero, R; Klümpen, HJ; Cremer, B; Sevilla, I; Eriksson, B; Tabaksblat, E; Metges, JP; Reed, NS; Schrader, J; Navarro, V; Valentí, V; Hernando, J; Colao, AM; Vestermark, L; Carnaghi, C; Knigge, UP; Jimenez-Fonseca, P; Benavent, M; de Vos-Geelen, J; Venerito, M; Von Werder, A; Jann, H; Rinke, A; Smith, D; Hörsch, D; Starling, N; Ruszniewski, P; Baudin, E; Caroli-Bosc, FX; Manzano, JL; Martín, M; Scarpa, A; Lawlor, RT; Ragulan, C; Ps, H; Sadanandam, A; Carmona-Bayonas, A; Salazar, R – 2025 – 10.1016/j.esmoop.2025.105922